百奧泰(688177.SH):預計半年度淨虧損1.1億元到1.4億元
格隆匯7月29日丨百奧泰(688177.SH)公佈,(1)經財務部門初步測算,預計2025年半年度實現歸屬於母公司所有者的淨利潤與上年同期相比,將減少虧損,實現歸屬於母公司所有者的淨利潤為-11,000.00萬元到-14,000.00萬元,減少虧損9,684.58萬元到12,684.58萬元。(2)預計歸屬於母公司所有者扣除非經常性損益後的淨利潤為-16,000.00萬元到-19,000.00萬元,將減少虧損8,033.49萬元至11,033.49萬元。
本報吿期公司業績較上年同期將實現減虧。主要原因一是公司積極拓展市場,阿達木單抗注射液(格樂立?)銷售額較上年同期穩步提升,公司營業收入較上年同期增加2,000.00萬元至5,000.00萬元;二是本報吿期研發費用較上年同期減少4,000.00萬元至7,000.00萬元,主要原因是公司部分研發項目已完成全球Ⅲ期臨牀,BAT2206、BAT2306和BAT2506項目均處於上市申請報批階段,其中BAT2206已獲得美國FDA上市批准,因此研發費用較上年同期減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.